No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	relugolix Sensitive: A1 - Approval relugolix Sensitive : A1	relugolix Sensitive: A1 - Approval relugolix Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	degarelix Sensitive: A1 - Approval degarelix Sensitive : A1	degarelix Sensitive: A1 - Approval degarelix Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	abiraterone acetate + degarelix Sensitive: A2 - Guideline abiraterone acetate + degarelix Sensitive : A2	abiraterone acetate + degarelix Sensitive: A2 - Guideline abiraterone acetate + degarelix Sensitive : A2
SNAI2 deletion	Prostate Cancer	SNAI2 deletion	Prostate Cancer	abiraterone acetate + degarelix + bicalutamide implant Sensitive: C3 – Early Trials abiraterone acetate + degarelix + bicalutamide implant Sensitive : C3	abiraterone acetate + degarelix + bicalutamide implant Sensitive: C3 – Early Trials abiraterone acetate + degarelix + bicalutamide implant Sensitive : C3

GnRH antagonist

Associations(4)